Stocktoria
BIO-TECHNE Corp TECH
BIO-TECHNE Corp (TECH) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.45% (safety: stretched). FY2025 revenue was $1.2B at a 6.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.02 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-09 | RBC Capital | Sector Perform (down) |
| 2026-06-30 | TD Cowen | Hold (down) |
| 2026-06-30 | Benchmark | Hold (down) |
| 2026-06-29 | Citigroup | Neutral (down) |
| 2026-06-26 | Stephens & Co. | Equal-Weight (down) |
| 2026-06-26 | William Blair | Market Perform (down) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.169 |
| Retained earnings / assets | 0.417 |
| EBIT / assets | 0.04 |
| Equity / liabilities | 3.003 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
| TARS | Tarsus Pharmaceuticals, Inc. | 4/9 | 2.84 | — | +146.7% |
About BIO-TECHNE Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
FAQ
Is TECH financially healthy?
BIO-TECHNE Corp's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does TECH pay a dividend, and is it safe?
Yes. BIO-TECHNE Corp pays a dividend yielding about 0.45% with a 68.7% payout ratio, rated “stretched” for safety.
How profitable is TECH?
In FY2025, BIO-TECHNE Corp had a net margin of 6.0% and a return on equity of 3.8%.
Is TECH overvalued or undervalued?
BIO-TECHNE Corp trades at about 157.0× trailing earnings — above its 10-year norm (10-year range 40.1×–138.6×, median 58.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for TECH?
The average Wall-Street price target for BIO-TECHNE Corp is $69.73, about 3.5% below the recent price, from 11 analysts (consensus: hold).
Is TECH a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BIO-TECHNE Corp: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 151.4×, a dividend yield of 0.45%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.